Clinical Image Open Access
Polycystic liver in autosomal dominant polycystic kidney disease
Han-Sheng Fang1,2,3, Wei Liu1,2,3,*
- 1The First College of Clinical Medical Science, China Three Gorges University, Yichang, China
- 2Institute of Digestive Disease, China Three Gorges University, Yichang, PR China
- 3Department of Gastroenterology, Yichang Central People’s Hospital, Yichang, PR China
Corresponding Author
Wei Liu, liuwei@ctgu.edu.cn
Received Date: July 16, 2025
Accepted Date: September 23, 2025
Fang HS, Liu W. Polycystic liver in autosomal dominant polycystic kidney disease. J Clin Exp Gastroenterol. 2025;4(1):15–16.
Copyright: © 2025 Fang HS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Drug delivery via the upper nasal space: A novel route for anesthesiologists, intensivists and emergency department physicians?
Many drugs are effective systemically, but slow onset of non-intravenous routes of administration may limit their clinical utility. While anesthesiologists usually have intravenous (IV) access for drug delivery, other healthcare professionals in less controlled situations such as acute crises in the emergency room, critical care settings, or urgent needs in the community, may need non-invasive drug delivery [1].
Molecular signatures of aggressive pediatric liver cancer
Liver masses account for 5 to 6% of pediatric cancer, which includes hepatoblastoma (HBL) along with rare cases of hepatocellular carcinoma (HCC). The most dangerous form of pediatric liver cancer is aggressive HBL, which can be characterized by chemo-resistance and multiple nodules or metastases at diagnosis, all correlating with worse clinical prognosis. Despite intensive studies and a significant improvement in overall outcomes, very little is known about the key molecular pathways which determine the aggressiveness of pediatric liver cancer.
COVID-19 and the Liver: Uncovering the Hidden Culprit behind Liver Injury
The effects of COVID-19 have been of increasing interest in all fields of medicine after the pandemic, especially considering the important impact and incidence of patients infected with coronavirus. Numerous studies have reported the vast clinical implications related to permanent organ and tissue damage after infection and long COVID.
Involvement of transient receptor potential in liver diseases
Transient receptor potential (TRP) family is a large superfamily of widely expressed ion channels. In recent years, several studies have been conducted on the mechanism of action of TRP. However, studies on the role of TRP in liver diseases are limited. In fact, TRP plays a vital role in the progression of many liver diseases, such as hepatic fibrosis, hepatocellular carcinoma, alcoholic fatty liver disease, and nonalcoholic fatty liver disease.
Dynamics of the ‘free’ maternal healthcare policy intervention in Ghana; Facility delivery utilization and neonatal mortality indices from a developing country setting
The one conceptual key to improving newborn healthcare outcomes is thought to be bridging the access gap to care, particularly in sub-Saharan Africa. However, recent studies have reported conflicting results relative to establishing a link between outcomes and access to care intervention programs.